BEMLAYO and DESIGN — 2450075
Application number
2450075
Type(s)
Design
Category
Trademark
CIPO Status
SEARCHED
TM5 status
LIVE/APPLICATION/
Under Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and that this application has been assigned to an examiner.
Filed
2026-01-15
Applicant
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285
UNITED STATES OF AMERICA
Agent
BORDEN LADNER GERVAIS LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9
Documents
Index headings
- BEMLAYO
- Y
Vienna information (Code & Description)
- 26.1.1
- Circles
- A 26.1.3
- One circle or ellipse
- A 26.1.18
- Circles or ellipses containing one or more letters
- A 26.1.19
- Circles or ellipses with inscriptions projecting beyond the circumference
- A 26.1.26
- Circles or ellipses with cutout areas
- 27.5.1
- Letters presenting a special form of writing
- A 27.5.8
- Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone diseases and disorders and musculoskeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, eczema, acne, rosacea, ichthyosis, vitiligo, uticaria and alopecia areata, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, diabetes, dyslipidemia, endocrine diseases and disorders, namely, growth and thyroid disorders, diabetes and obesity, and hormonal diseases, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases, inflammatory muscle diseases and disorders, anti-inflammatory preparations, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental health disorders, metabolic diseases and disorders, namely, diabetes, gout, arthritis and anemia, obesity, hyperlipidemia, insulin resistance and metabolic syndrome, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, namely, Alzheimer's, Huntington's disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, amyotrophic lateral sclerosis (ALS), encephalitis, meningitis, muscular dystrophy, myasthenia gravis, dystonia, epilepsy, seizures, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases.
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2026-01-15 | ||
| Created | 2026-01-15 | ||
| Formalized | 2026-01-15 | ||
| Pre-Assessment Letter Sent | 2026-01-29 | Acceptable Goods or Services | |
| Search Recorded | 2026-10-01 | ||
| Examiner's First Report | 2026-10-01 | 2027-04-01 |